Figure 2.

Cost-effectiveness acceptability curve for scenarios A and B. Scenario A includes a CEA with QALYs and a placeholder treatment cost of $1,038,093. Scenario B includes a CEA with evLYG and a placeholder treatment cost of $1,485,635. Both scenarios assume 3.0% discounting of costs and benefits.
Dashed line, SoC alone; solid line, delandistrogene moxeparvovec plus SoC.
evLYG, equal value life years gained; QALY, quality-adjusted life year; SoC, standard of care, WTP, willingness-to-pay.